• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Stevanato Group Launches After-sales Service Offering

    X-Chem Acquires IntelliSyn and AviSyn

    Aphena’s $21M Cookeville Expansion Nears Completion

    BioMed X, Janssen Enter Oral Drug Delivery Alliance

    Care Access Research, AstraZeneca Partner on COVID-19 Antibody Trial
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Aphena’s $21M Cookeville Expansion Nears Completion

    PromoCell Receives EXCiPACT Certification

    Civica to Build an Essential Medicines Manufacturing Facility in Virginia

    Humanigen, Emergent Enter Covid-19 Partnership

    Samsung Bioepis Opens New Headquarters
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Aphena’s $21M Cookeville Expansion Nears Completion

    Civica to Build an Essential Medicines Manufacturing Facility in Virginia

    WDSrx Expands Warehouse Network

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    The Future of Clinical Trials Series: Part II

    X-Chem Acquires IntelliSyn and AviSyn

    Care Access Research, AstraZeneca Partner on COVID-19 Antibody Trial

    Caprion-HistoGeneX Rebrands as CellCarta

    Humanigen, Emergent Enter Covid-19 Partnership
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Reed-Lane

    Syngene

    Almac Group

    Baxter BioPharma Solutions

    Emergent BioSolutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Aphena Pharma Solutions

    Cytovance Biologics

    Syngene

    Emergent BioSolutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Outsourcing Partnerships: Trends in the CDMO Sector

    The market for outsourcing services is growing faster than the pharmaceutical industry as a whole.

    Outsourcing Partnerships:  Trends in the CDMO Sector
    Related CONTENT
    • The Future of Clinical Trials Series: Part II
    • FDA Approves Janssen’s CABENUVA
    • JS Bio and Etta Biotech Advancing Partnership
    • Virtual Clinical Trials: The Future of Dermatology Studies
    • LSNE Expands Fill Finish and Lyophilization Ops
    Tim Wright, Contract Pharma09.06.17
    The advantage of outsourcing development and manufacturing services is that it allows pharma companies to focus on their core business, such as R&D and marketing, which can crucially reduce costs, time-to-market, and risk. Contract Pharma talks with leaders at several CDMOs about current trends in outsourcing and the importance of investment in CDMO partnerships in today’s pharma landscape.

    Contract Pharma: How have outsourcing relationships evolved over the last 10 years?

    Claire Madden-Smith, senior vice president, Juniper Pharma Services: The last decade has seen a paradigm shift in outsourcing relationships. Where once outsourcing was driven largely by a desire to reduce costs of routine or commodity based activities, today we see additional factors such as technical expertise, improved operational efficiency, access to innovation and risk management being equal or primary drivers towards outsourcing. With the resurgent investment in biotech development over the last five years, the relationship between sponsor and vendor has become much more collaborative.

    Colin Mackay, founder and chief executive officer, Symbiosis: There has been significant consolidation in the contract manufacturing sector, meaning the industry is less fragmented with fewer bigger service providers. This reduces the choices available to drug developers when selecting partners to work with to develop their promising molecules. As a result, relationships seem to be a lot more about strategic partnerships and less about straightforward operational outsourcing.
    Symbiosis has proactively nurtured relationships with many small biotechs and specialty pharma companies who are looking for a partner that they can grow with. As such, the cultural fit with their chosen CMO is as important as technical capabilities and levels of compliance, which may not have been where the emphasis was placed 10 years ago.

    Anthony Sheehan, chief executive officer, Saneca Pharma: We have seen many pharmaceutical companies redefine their offering and sell off parts of their business in order to allow their in-house resources to focus on core business areas where they have the most success. By outsourcing additional services according to customer demand, companies have been able to make huge cost and time savings. In fact, Saneca Pharma was born out of this type of divestment and has a big pharma heritage, having previously existed as a Sanofi site.

    This trend has had a positive effect on CDMOs who are seeing a higher demand for a broader range of outsourced services to plug the gaps in their customers’ in-house capacity. As a result, many CDMOs are expanding their offering to become full-service providers that can offer a wider variety of capabilities in order to remain competitive. While smaller, niche service providers will continue to exist, there is an increased focus on developing ‘true partnerships’ with CDMOs that are able to provide a multitude of services. When a CDMO can do this from one single site this helps to further streamline the supply chain for its customers.

    Mark Quick, executive vice president, corporate development, Recipharm: Outsourcing relationships are now much more strategic. The decision to outsource is made at an earlier stage in a product’s development, rather than being used as a backup when things go wrong, or when resources get stretched. Consequently, long-term partnerships are becoming more commonplace. The growing financial pressures placed on pharmaceutical companies is one reason for this shift, as they look to make cost and time savings by outsourcing to CDMOs with specialist capabilities. This, together with a number of CMO failures, has led to companies more stringently evaluating contract partners. Companies with strong compliance track records and a good financial history tend to fair better with this scrutiny.

    Manuel Leal, business development director, Idifarma: The outsourcing industry continues to grow. The increasing importance of generics, which has driven competition in the pharmaceutical sector generally, has led to a significant increase in outsourcing, mostly when specific capabilities like high potency or small-scale manufacturing are required. Customers now expect increased flexibility and the ability to adapt to products with special demands in terms of manufacturing conditions, available technologies, smaller volumes, global distribution, etc. Also, the service level demands have increased and customers want better response times from trusted CDMOs, without compromising the highest quality standards.

    CP: In your opinion, what does it take to maintain an effective sponsor-partner relationship?

    Madden-Smith: In my experience, the most effective relationships are those built on a shared understanding of the primary end goals and assumptions. Effective communication on all sides, working together as a single team and continuously checking assumptions is paramount to keep the drug development activities on the most efficient track towards a successful and robust product.

    Mackay: CMOs need to invest in building a successful relationship with each client based on a clear understanding of a specific clients’ definition of an ideal outcome. Only then can a true partnership begin to be established.

    If you are a smaller, specialist CMO like Symbiosis, we need to demonstrate how we are best placed to overcome specific challenges that a customer may encounter and offer a niche competitive strength, which our competitors can’t. For example, while larger CMOs offer relatively fixed service offerings, as a small-scale sterile manufacturer, we have the operational flexibility to meet tight timescales and tailor our services directly and specifically in response to a clients’ requirements. So, if time is of the essence, our agility and speed of delivery resonates strongly with our clients.

    In terms of maintaining a relationship, an organization will only have a relationship to be concerned about if it started out with its eyes and ears open, and with an intention to build a relationship, which is a long-term one. Generally speaking, those organizations who focus on volume, or are naturally transactional in their dealings with customers, tend to concern themselves less with the issue of maintaining relationships. Our small-to-medium clients don’t see value in that approach.

    Sheehan: It’s critically important to fully understand your customer and their expectations. Underestimating the scope of a contract and failing to deliver will have a lasting effect on sponsor-partner relationships. Taking the time to fully comprehend the challenges your customer is facing is vital to maintaining a strong partnership. For example, Saneca Pharma works with many pharmaceutical companies who not only value technical capabilities and expertise, but also flexibility and open communication, meaning it’s important our teams are responsive and can adapt to changing requirements. In a densely populated market, a quality service offering combined with a broad portfolio of capabilities to provide the agility needed in this fast-moving sector can really help CDMOs to stand out.

    Quick: The answer here is not rocket science. You need to provide customers with the services they want and deliver what you say you will. Of course, cost is always a factor in any outsourcing decision, so providing good value for money is also important. The ability to manage complexity is also fundamental to an effective relationship. Our customers come to us for guidance on development and manufacturing challenges and it is our job to manage these on their behalf, removing the headache. A focus on innovation is the only way to make this happen; you need to improve and innovate all the time, whether this is to overcome complex formulation challenges, reduce lead times during manufacturing or minimize cost. Those CDMOs that provide a full-service offering are best placed to offer a turnkey solution to customer challenges and therefore build effective, long-term relationships.

    Leal: We look for long-term strategic collaborations with clients. We always strive to integrate with customers through a client-centric approach to build mutual trust and transparency. This trust is often generated in complex moments within a project so it’s essential to be upfront with the client, dedicating time to the clear definition of roles and expectations at the outset, as well as being proactive when solving technical challenges.

    CP: What should pharmaceutical companies be considering when choosing an outsourced partner?

    Madden-Smith: By the very nature of dealing with the unknowns of new chemical entities, drug development has many twists and turns which need careful navigation and require different expertise sets at different stages. Obviously, compliance records, costs and expertise are important but most companies will look competitive in these areas, so it is important to think more strategically.

    In the CDMO world, when a pharmaceutical company is considering an outsource partner they should have considered what their success looks like long term and be planning for achieving that best chance of success. Starting with the finish in mind, enables the foundational concepts around a target product profile to be produced, which acts as an excellent guide to the enormity or simplicity of the task at hand. The consideration should then be around whether a generalist outsourcing partner will suffice or whether specific areas of expertise are critical to product development success. 

    Based on this type of approach it is possible to then be specific in the analysis of which CDMOs or even multiple CDMOs best fit the need. That is, if you have a challenging molecule with a high risk of failing to achieve relevant bioavailability, it would make no sense to focus on a great CMO, if they lack innovative expertise in early formulation development phases. Likewise, if you have a challenging timeline you would want to consider which company can be most nimble to respond whilst still providing expertise in development of a robust validated product. 

    However, where the product development follows a more conventional path, then a generalist CDMO offering cost effective development will clearly suffice. This type of risk-based approach would hopefully avoid costly mistakes of either under or over estimating the criticality of each development step.

    Mackay: Regulatory compliance, technical capability and operational flexibility are core client service expectations that we believe need to be demonstrated in today’s competitive environment.

    As mentioned, we believe that cultural fit is also fundamentally important. We ideally partner with dynamic, fast-growing companies, who are pragmatic yet focused on achieving the core project objectives. Smaller drug developers are more likely to want to partner with smaller CMOs that will value their business and offer real experience to help them navigate the drug development landscape. We’ve heard time and time again from smaller drug developers that they don’t like to feel like a little fish in a very large pond, which is often the case when using a larger, one-stop-shop style CDMO.

    Sheehan: As a result of the supply chain efficiencies, such as reduced lead times and cost savings, that can be gained from using a single supplier, it’s becoming increasingly common for pharmaceutical companies to seek a turnkey service from CDMOs to support taking their products through the entire product lifecycle. The broader the scope of services your CDMO can offer the better, particularly if you’re looking to develop a long-term partnership. A wider service offering could meet the requirements of future products too and mitigate the task of finding a new, reputable CDMO for each project. In addition to a breadth of services and technologies, your contract partner should also have a responsive and experienced team that can help to overcome development, manufacturing and distribution challenges as well as adding genuine value to your operations.

    Quick: Firstly, due to the nature of our industry, quality standards and compliance culture are key. Pharmaceutical companies should also consider the range and breadth of services offered by a contract partner and its geographic reach, as ultimately, this will help to simplify and streamline their supply chain. At present, the greatest challenge faced by CMOs is the upcoming deadlines for pharmaceutical serialization in the U.S. and Europe. When choosing an outsourced partner, it’s important to assess its serialization program and how prepared it is to meet the 2017 and 2019 compliance requirements. There is a likelihood that many CMOs will not be ready to supply serialized drug products and this will have a serious impact on product supply into key markets.

    Leal: Besides the required technical capabilities, it’s important pharmaceutical companies choose a partner that is client-orientated—having the customer as the ‘end goal’ and not just as a means to other objectives. It also takes long-term focus, a clear and well-defined business model and the avoidance of conflicts of interest, which inevitably appear if the CDMO has its own product portfolio, for instance.

    Alignment and integration with the customer as well as reliability, responsiveness and flexibility remain very important factors for long-term success.

    CP: In which areas of drug development and manufacturing are you seeing the greatest demand for outsourcing?

    Madden-Smith: In general, the CDMO sector across the board has seen considerable annual growth over the past five years. Specifically, at Juniper we have seen an increased outsourcing tendency for preclinical and early Phase I and II development activities where there are challenges around small molecule APIs, for example poorly water-soluble drugs. Clients are increasingly coming to CDMOs that can bring a breadth and depth of expertise to the development and manufacture of dosage forms, to deal with significant technical challenges.

    Mackay: We have experienced significant growth in the U.S. market in recent years, with the North American market now accounting for over a third of our revenues. We expect that to continue as demand from U.S.-based biotechnology firms looking for small scale aseptic manufacturing capabilities to support clinical trials increases in line with their collective financial good health.

    However, with a shift towards the development of personalized medicines among emerging biotech and pharma companies and a greater need for cytotoxic products, there will be a greater need than ever before for specialist CMOs that can rapidly manufacture small (and potentially complicated) batches for small patient populations.

    Sheehan: There is growing demand for controlled release technologies that can optimize the performance of novel and existing drugs by reducing the potency of a product or the risk of dose dumping and adverse side effects. Given the level of skill and technical expertise required to develop and manufacture controlled release dosage forms, pharmaceutical companies are increasingly asking their CDMOs for these services. CDMOs with years of expertise in this area can help drug manufacturers to speed-up time to market and reduce the overall cost of developing and manufacturing drugs in this way. There is also growing demand for controlled substances, which require specialist facilities and in some cases controlled release technology. Our site was originally established in 1941 to produce morphine active pharmaceutical ingredient (API) and controlled substances in API and finished dosage form (FDF), which is still a focus area for Saneca Pharma today.

    Quick: This very much depends on the type of customer. While big pharma may use CDMOs for greater flexibility and efficiency throughout the drug development lifecycle, smaller companies, including the growing number of virtual pharma firms, rely on contract partners to access specific specialist services, expertise or manufacturing capacity that they do not have in-house. Outsourcing is particularly prevalent in areas where specialist technology and expertise is required, so we are experiencing increasing demand for our development services. This is particularly the case in areas including formulation development, clinical supply manufacture and trial management to achieve first in human milestones, as well as chemistry services.

    In terms of manufacturing, the greatest demand remains in the production of solid dosage forms, representing more than 47 percent of the CDMO market. However, the manufacture of injectables is set to rise and reach 46 percent of the market share by 2020. This is directly related to the increasing development of cytotoxic drugs and biologics.

    Leal: There are many opportunities in specialized or niche contract manufacturing. The capacity to handle highly potent compounds and the flexibility to manufacture small-scale batches are becoming very important for many of our customers and products. The availability of innovative technological platforms able to improve cost and process efficiencies, product safety and bioavailability or patient compliance also constitute a number of growth opportunities.

    CP: How do you see the future of outsourcing and what will the impact be on current sponsor-partner relationships?

    Madden-Smith: The outsourcing trend looks set to continue for the foreseeable future and we are seeing more long-term strategic relationships building where, not only is there a technical fit but also a strong cultural fit between sponsor and partner.

    Mackay: We envisage the outsourcing sector to continue to grow steadily and it is showing no signs of slowing down. In a recent industry survey, the OSP William Reed State of the Industry report 2017, 44 percent of pharmaceutical companies surveyed said they expect to outsource more business this year than last, which is interesting market feedback.
    We therefore expect this trend to continue, with growth in the parenteral manufacturing space coming from biopharma companies as they continue to progress new drug products to market, significantly driven by an increase in industry funding.

    While many CMOs continue to expand their offerings, there will continue to be demand for niche manufacturing services from specialist providers that can offer the flexibility needed to meet increasingly tight timescales in the drug development pipeline.

    Success in outsourcing is underpinned by technical capabilities and effective communication in the sponsor-partner relationship. As a result, we expect to see more and more clients moving away from tactical outsourcing initiatives in favor of a relationship-oriented strategic partnership with CMO partners across a collaborative supply chain.

    Sheehan: It is likely that the CDMO landscape will continue evolve, perhaps at a slightly slower pace, further changing the relationship between contract partners and their customers. New and more challenging drugs entering the supply chain will continue to drive the demand for comprehensive development services, particularly controlled release technologies. There will continue to be demand for competitive pricing, without compromising on quality. Whereas in the past companies have looked to Eastern countries, such as India, to generate these savings, increasing concerns surrounding the quality of drugs produced in this market means more and more pharmaceutical companies are keen to move their operations back to Europe. With this in mind, full-service CDMOs in lower cost markets such as Slovakia will find themselves ideally placed to deliver a service that combines cost effectiveness, quality, technical expertise and speed-to-market.

    Quick: Ongoing transformations in the pharmaceutical industry, including pricing pressures, more stringent regulation, modernization and market complexities, are all driving demand for outsourcing and we expect this to continue in the years to come. As the population continues to age and we see higher incidence of lifestyle and chronic ailments, demand for innovation and new drug development will grow too. As the CDMO space is subject to more and more consolidation, we expect that pharmaceutical companies will begin to work with a smaller number of contract partners that are able to deliver a wider range of services. This will help to simplify the supply chain, enable the development of closer, more strategic relationships and ultimately, speed up new drugs to market. Pharma companies will continue to rationalize their manufacturing footprint and focus on their core business, while more virtual companies will appear with limited infrastructure. Both of these trends will help to feed CDMO pipelines and allow the outsourcing sector to grow. Pharmaceutical demand in emerging markets is also expected to increase between eight and nine percent per annum until 2020 and pharmaceutical companies will naturally evaluate CDMOs in terms of location/ proximity to market, labor cost and the ability to meet variable demand.

    Leal: The higher efficiency of the outsourcing model in the pharma industry will lead to sustained growth, helped by factors such as the need for higher specialization. There is still room for improvement though: it is necessary for all parties involved to move from tactical collaborations to real strategic partnerships and then to client-supplier integration in order to be totally flexible and fully exploit the potential of outsourcing. This will help products keep competitive in the market while complying with the growing regulatory requirements. 
    Related Searches
    • Parenteral Manufacturing
    • Sterile
    • sanofi
    • biologics
    Suggested For You
    The Future of Clinical Trials Series: Part II The Future of Clinical Trials Series: Part II
    FDA Approves Janssen’s CABENUVA  FDA Approves Janssen’s CABENUVA
    JS Bio and Etta Biotech Advancing Partnership JS Bio and Etta Biotech Advancing Partnership
    Virtual Clinical Trials: The Future of Dermatology Studies Virtual Clinical Trials: The Future of Dermatology Studies
    LSNE Expands Fill Finish and Lyophilization Ops LSNE Expands Fill Finish and Lyophilization Ops
    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact
    Alcami Expands Oral Solid Capabilities with Investment in Wilmington, NC Alcami Expands Oral Solid Capabilities with Investment in Wilmington, NC
    BrickBio Inks ADC Co-Development Deal BrickBio Inks ADC Co-Development Deal
    Samsung Biologics Names John Rim as President and CEO Samsung Biologics Names John Rim as President and CEO
    Navigating Uncertainty: Considerations for Life Sciences 2021 Navigating Uncertainty: Considerations for Life Sciences 2021
    Catalent Appoints Minakuchi Facility GM Catalent Appoints Minakuchi Facility GM
    BD to Invest $1.2B in Pre-Fillable Syringe Manufacturing Capacity BD to Invest $1.2B in Pre-Fillable Syringe Manufacturing Capacity
    Asymchem Asymchem
    Life Science Success Podcast: Matt Hicks Life Science Success Podcast: Matt Hicks
    Frontida BioPharma Appoints EVP Technology Frontida BioPharma Appoints EVP Technology

    Related Features

    • Excipients
      Bye-Bye China?

      Bye-Bye China?

      Instead of closing its doors on China, Western pharma industry needs to take a balanced approach and perform proper due diligence based on objective criteria.
      Michele Jermini and Enrico Polastro 11.17.20

    • Clinical Trials | Information Technology | R&D
      Decentralized Trials Fuel AI Revolution in Clinical Research

      Decentralized Trials Fuel AI Revolution in Clinical Research

      The life sciences industry is giving clinical a full makeover, dramatically improving how new therapeutics are developed.
      Nick Moss, Vice President of Analytics and Machine Learning, Medable 11.17.20

    • Drug Delivery | Injectables
      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Bringing together self-medication with auto-injectors and sustainable secondary packaging.
      Matthias Heinrichs, Head of Product Management and Project Engineering, Syntegon Technology 11.17.20


    • The Single-Use Mixing Landscape: Evaluating Your Options

      The Single-Use Mixing Landscape: Evaluating Your Options

      Adoption of single-use technologies has increased markedly in recent years and will continue to grow.
      Mark A. Sitcoske, Founder & CEO, High Purity New England 11.17.20

    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      Lonza’s Director of Commercial Development, Sean Diver, was recently named President of DCAT.
      Tim Wright, Editor, Contract Pharma 11.17.20

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20


    • Injectables
      Catering for the Complex

      Catering for the Complex

      The rapidly changing landscape of pharmaceutical packaging.
      Marcelo Cruz, Director Business Development and Marketing, Tjoapack 11.17.20

    • Cold Chain Management | Supply Chain
      Cold Chain Trends

      Cold Chain Trends

      There is a growing need for convenience through Direct-to-Patient and Direct-from-Patient services in clinical trials.
      Vince Paolizzi, Director of NanoCool Sales, Pelican BioThermal 11.17.20

    • Biologics, Proteins, Vaccines | Inspections | Supply Chain
      Inspecting the Unexpected

      Inspecting the Unexpected

      Preparing quality control processes for COVID-19 vaccine candidates.
      Dr. Andrea Sardella and Raffaele Pace, Stevanato Group 11.17.20


    • Scale-up/Technology Transfer
      Ensuring Quality During the Transfer and Scale Up of Rx Drugs

      Ensuring Quality During the Transfer and Scale Up of Rx Drugs

      Defining the key parameters and considerations for a successful technology transfer.
      Tom Chang, President, Bora Pharmaceutical Laboratory Co. Ltd. 11.17.20

    • Scale-up/Technology Transfer
      Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up

      Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up

      Identifying, assessing and mitigating threats at every stage of the development pipeline.
      Joe Willmot, Application Leader, H.E.L Group 11.17.20

    • Clinical Trials | Information Technology
      The Role of Electronic Monitoring in Maintaining Medication Adherence

      The Role of Electronic Monitoring in Maintaining Medication Adherence

      Digital solutions offer hope to get patients to take their medications properly.
      Bernard Vrijens, Scientific Lead, AARDEX Group 10.14.20


    • APIs
      Understanding the Importance of Crystallization Processes

      Understanding the Importance of Crystallization Processes

      Crystallization is a crucial aspect of a molecule’s development and can be used to avoid unnecessary cost, risk and development delays.
      Dr. Craig Callahan, Project Scientist, Cambrex Edinburgh 10.14.20

    • Capsules | Solid Dosage/Creams/Ointments
      Capsule Technology Trends

      Capsule Technology Trends

      A look at the capsule market with a particular focus on the factors driving increased demand in non-gelatin-based formulations.
      Julien Lamps, Product Manager, Lonza 10.14.20

    • Aseptic Processing | Fill/Finish
      A Holistic Cleanroom Concept: Higher Quality and Greater Flexibility

      A Holistic Cleanroom Concept: Higher Quality and Greater Flexibility

      Overcoming today’s aseptic fill-and-finish process challenges.
      Ute Schleyer, Project Manager, Site & Plant Development, Vetter 10.14.20

    Trending
    • Integrated Continuous Manufacturing ICM
    • Humanigen, Emergent Enter Covid-19 Partnership
    • Samsung Bioepis Opens New Headquarters
    • CDMO Northway Biotech Expands In U.S.
    • CONTINUUS Awarded $69.3M DoD Grant
    Breaking News
    • Stevanato Group Launches After-sales Service Offering
    • X-Chem Acquires IntelliSyn and AviSyn
    • Aphena’s $21M Cookeville Expansion Nears Completion
    • BioMed X, Janssen Enter Oral Drug Delivery Alliance
    • Care Access Research, AstraZeneca Partner on COVID-19 Antibody Trial
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Kerry Launches Web-Based Tool for Plant-Based Formulation Challenges
    Wiley’s Finest Earns Accolades for Taste of Omega-3 Products
    Clinical Evidence Suggests Potential Oral Benefits for Curcumin Extract
    Coatings World

    Latest Breaking News From Coatings World

    Scott McLaughlin to Race in PPG Colors During Rookie INDYCAR Season
    Vink Chemicals Offers parmetol PSG
    Palmer Holland Expands Roles, Positions Of Business Teams
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Butterfly Network Appoints New Leader
    BD Names Chairman of Board
    Interplex Acquires OCP Group
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Stevanato Group Launches After-sales Service Offering
    X-Chem Acquires IntelliSyn and AviSyn
    Aphena’s $21M Cookeville Expansion Nears Completion
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    The Estée Lauder Companies Announces Game-Changing Sustainability Goals for Travel Retail
    Aura Introduces Customizable Hair Care
    Corpack Creates Custom Packaging for Marlies Möller Hair Care Line
    Happi

    Latest Breaking News From Happi

    Harry’s Launches ‘Headquarters’
    Henkel Recognizes Top Suppliers
    Estée Lauder Travel Retail's Sustainability Goals
    Ink World

    Latest Breaking News From Ink World

    Smurfit Kappa Sets New Sustainability Targets with Better Planet 2050
    Paragon Expands Direct Mail Capabilities with Ricoh Pro VC70000
    Rondo Ganahl Adds Koenig & Bauer Durst Delta SPC 130
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Great Lakes Label debuts new website
    Epson partner creates label applicators for pharmaceutical products
    ACTEGA removes chemicals from laminating adhesives
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    American Made Production Equipment for Mask Manufacturers
    Kimberly-Clark Releases Q4, Full Year Results
    Freudenberg to Establish Apparel Interlining Competence Centers
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Spinal Elements' Lucent XP-Curved Expandable TLIF Gains FDA Nod
    FDA OKs OrthoSpin's 2nd Gen Robotic, Digital External Fixation System
    Nextremity Solutions Enters Supply Agreement with Fort Wayne Metals
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    North American Semiconductor Equipment Industry Posts December 2020 Billings
    First Solar Signs Definitive Agreement to Sell US Development Platform to Leeward
    PRINTING United Alliance Announces TAGA Presents Virtual Event

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login